At long last luvelta-T is shelved, and Sutro seeks a new focus.
ApexOnco Front Page
Recent articles
The Japanese group licenses sapablursen from Ionis for $280m.
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
The French group takes a shot at Perspective with its second bet on Orano Med.
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
The Hutchmed-originated savolitinib moves towards its first US approval.
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.